1989 Fiscal Year Final Research Report Summary
Research on pathogenesis, epidemiology and treatment for HTLV-I related neurological disorders
| Project/Area Number |
63304042
|
|---|
| Research Category |
Grant-in-Aid for Co-operative Research (A)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Neurology
|
|---|
| Research Institution | Kagoshima University |
|---|
Principal Investigator |
IGATA Akihiro Kagoshima University, President, 学長 (00010207)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
SONODA Shunro Kagoshima University, Faculty of Medicine, Associate Professor, 医学部, 助教授 (40036463)
SATO Eiichi Kagoshima University, Faculty of Medicine, Professor, 医学部, 教授 (60004579)
NAGATAKI Shigenobu Nagasaki University, Faculty of Medicine, Professor, 医学部, 教授 (70010311)
AKIYAMA Shinichi Kagoshima University, Faculty of Medicine, Professor, 医学部, 教授 (60117413)
OSAME Mitsuhiro Kagoshima University, Faculty of Medicine, Professor, 医学部, 教授 (10041435)
|
|---|
| Project Period (FY) |
1988 – 1989
|
| Keywords | HTLV-I / HAM / TSP / HTLV-I-Associated / Spastic Paraparesis / Retrovirus / Polyarthritis / alpha-Interferon / ハム |
|---|
| Research Abstract |
Our recent investigation revealed that human lymphotropic virus type I (HTLV-I) can cause a chronic neurological disorder which was named HTLV-I-associated myelopathy(HAM) by Osame et al in 1986. The purpose of this project was to elucidate the pathomechanism, epidemiology and treatment of HTLV-I related neurological disorders including HAM. This research project could obtain the following fruitful results: 1) The viruses detected in ATL and HAM are identical on DNA blotting. 2) Increased replication of HTLV-I in HAM was observed. 3) HLA haplotype-linked high immune responsiveness against HTLV-I was observed in HAM, when compared with ATLL. 4) The identity of HAM and tropical spastic paraparesis was established. 5) High incidence of pulmonary involvement, polyarthritis, and uveitis was found in HAM. 6) alpha-interferon and prednisolone were found to be effective for the treatment of HAM.
|
